Breaking News, Collaborations & Alliances

J&J Selects Lead Vaccine Candidate for COVID-19

Together with BARDA commits more than $1 billion to novel coronavirus vaccine R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson has selected a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020.   The company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.   Through a landmark new partnershi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters